18 July 2023 in Contraception and Reproductive Medicine
Background: In sub-Saharan Africa, tubal factors are described as the main aetiological factors of infertility. Under these conditions, medically assisted procreation is particularly indicated. However, Assisted Reproductive Technology centres are less available. Thus, infertile couples are quickly oriented towards available alternative conventional treatments. The present study aimed to determine the aetiological factors of infertility, the outcomes of the therapeutic options offered, and the factors associated with the success of conventional treatment among infertile couples seeking tertiary care in Kisangani. Methods: A cross-sectional study was conducted at two tertiary health facilities in Kisangani. Infertile couples who provided consent underwent specific examinations necessary for the exploration of infertility and were treated and followed up for a minimum of 6 months. The therapeutic options that were offered were expectant attitude, medical treatment, surgical treatment or transfer to an in vitro fertilization unit. The pregnancy diagnosis was performed by ultrasound. Results: A total of 272 infertile couples underwent specific examinations, were treated and were followed up for a minimum of 6 months. Many determinant causes were mostly linked to wives rather than husbands. Overall, only 34 women among 211 who were treated became pregnant during the follow-up period; 61 couples were advised to resort to IVF or adoption, but the couples for whom expectant the attitude was indicated immediately rejected it. The patients who therapeutically succeeded at the end of the treatment were those who were younger than 35 years (OR = 2.27; 95% CI = 1.06–4.87; P = 0.017), had a duration of infertility of less than five years (OR = 6.08; 95% CI = 1.79–20.69; P = 0.001) and had secondary infertility (OR = 6.08; 95% CI = 1.79–20.69; P = 0.001). Conclusion: Kisangani faces a major issue in the treatment of infertility. Treatment of patients using conventional methods is limited by the predominance of tubal factors as aetiological determinants of infertility. The low pregnancy rate found in this study provided additional evidence of this. This paper represents a serious plea to national policy-makers to encourage them to pay attention to issues surrounding infertility.
4 January 2021 in British Journal of Clinical Pharmacology
25 February 2020 in Infectious Diseases in Obstetrics and Gynecology
BJBosenge Nguma Jean-Didier
Bosenge Nguma Jean-Didier
MMMaindo Alongo Mike-Antoine
Maindo Alongo Mike-Antoine
MJMbo Mukonkole Jean-Paulin
Mbo Mukonkole Jean-Paulin
MJManga Okenge Jean-Pascal
+1
Background. Gestational malaria is a major public health problem. It produces fetal complications such as low birth weight, perinatal mortality, and congenital malaria. The present study is aimed at determining the prevalence of congenital malaria and its neonatal complications in the city of Kisangani. Methods. We conducted a cross-sectional study in Kisangani from 1 January to 30 September 2018. Our study population was composed of 1248 newborns born in our study sites, during the period of our study. Just after their birth, we performed the thick drop smear in the placental print and in umbilical blood smear. Results. The prevalence of congenital malaria was 13.98%; 69.23% of newborns who contracted congenital malaria were from 18- to 34-year-old mothers, 53.85% from primiparous mothers, 92.31% from mothers who took intermittent preventive treatment in pregnancy with Sulfadoxine-Pyrimethamine, all (100%) from mothers using the insecticide-treated mosquito nets and 7.69% from HIV-positive mothers. Low birth weight and perinatal mortality were recorded in 76.92% and 7.69% of congenital malaria cases, respectively. Intermittent preventive treatment in pregnancy with Sulfadoxine-Pyrimethamine had no effect on congenital malaria (; OR: 0.8, 95% CI: 0.1651-3.8769) and on low birth weight (; OR: 1.2308, 95% CI: 0.0037-0.1464); however, it seemed to have protective effect against perinatal mortality (; OR: 0.0233, 95% CI: 0.0037-0.1464). Conclusion. Congenital malaria remains a major problem in stable malaria transmission area like Kisangani, and it is grafted by major perinatal complications, particularly low birth weight and perinatal mortality. We recommend an extended study to clarify the relationship between the outcome of pregnancy and the intermittent preventive treatment in pregnancy with Sulfadoxine-Pyrimethamine.
5 November 2025 in BMC Women's Health
JSJean-Jeanntot Juakali Sihalikyolo
Jean-Jeanntot Juakali Sihalikyolo
+2
Unexplained infertility (UI) affects 15–30% of infertile couples. This can be a very distressing experience for couples and challenging for clinicians because the diagnostic evidence is still weak. This study aimed to determine the risk factors for UI and its correlation with both bacterial vaginosis (BV) and anti-sperm antibodies (ASAs) among Congolese women. A matched case‒control study was conducted from August 2023 to July 2024. The sample included 144 individuals with UI and 144 fertile nonpregnant women attending postnatal consultations at Hôpital du Cinquantenaire de Kisangani. Logistic regression analysis was used to ascertain the determinants of UI, and the Phi (φ) coefficient was computed to evaluate correlations. Independent risk factors for UI included businesswomen (AOR = 4.21 [1.81–9.77]), resourceful women (AOR = 7.32 [1.59–33.77]), university education (AOR = 1.88 [1.02–3.46]), polygamous unions (AOR = 2.49 [1.16–5.37]), obesity (AOR = 2.21 [1.34–3.65]), sex with casual partners (AOR = 10.21 [3.45–30.17]), alcohol consumption (AOR = 1.83 [1.13–2.96]), use of indigenous products in the vagina (AOR = 2.41 [1.01–5.76]), premature menarche (AOR = 3.59 [1.136–11.37]), unsafe abortion (AOR = 5.93 [2.01–17.48]), BV (AOR = 8.91 [4.83–16.44]), and positive ASA (AOR = 14.9 [8.18–27.13]). BV (φ coefficient = 0.38) showed a moderate positive correlation with UI, and ASA (φ coefficient = 0.50) exhibited a strong positive correlation. UI among Congolese women was linked to sociodemographic, behavioural, and clinical factors. BV and ASA emerged as major correlates of UI. While these associations highlight the multifactorial nature of UI, causality cannot be inferred. Comprehensive infertility evaluations should consider screening for BV and ASA. Future research should investigate the management of ASA and BV in relation to UI to enhance fertility outcomes.
20 February 2024 in International Journal of Infectious Diseases
Objectives: Group B Streptococcus (GBS) is the leading infectious cause of stillbirth and neonatal morbidity and mortality in sub-Saharan Africa. Methods: Vaginal and rectovaginal swab samples were obtained from 274 intrapartum pregnant women in the Democratic Republic of the Congo to be analyzed for GBS DNA detection in parallel by the pointof-care BIOSYNEX AMPLIFLASH (R) GBS assay (Biosynex SA, Illkirch-Graffenstaden, France) and by reference quantitative polymerase chain reaction (qPCR). Results: Rectovaginal swabbing, nearly two-fold more positive for GBS than vaginal swabbing alone, showed a high prevalence of GBS DNA positivity in 20.1% of eligible intrapartum pregnant women. In the event of significant bacterial carriage (i.e., cycle threshold <= 33 by reference qPCR), the AMPLIFLASH (R) GBS assay with rectovaginal swabbing showed high sensitivity (98.1%) and specificity (10 0.0%) for GBS DNA detection, with excellent concordance, reliability, and accuracy with the reference qPCR, and positive predictive values and negative predictive values above 99.0%. Conclusions: The study demonstrates a high rate of female rectogenital GBS colonization in pregnant Congolese women. The AMPLIFLASH (R) GBS assay harbored excellent analytical performances in the field, which makes it suitable to be used as point-of-care molecular assay in various hospital and non-hospital settings where rapid diagnosis of GBS is necessary. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
9 October 2024 in Contraception and Reproductive Medicine
RDRoland Marini Djang’eIng’a
Roland Marini Djang’eIng’a
+2
This study aimed to assess the effect of sildenafil citrate and estradiol valerate as adjuvant therapy during ovarian stimulation cycles with clomiphene citrate in patients with unexplained infertility in Kisangani. A double-blind, randomized controlled trial was conducted for two years at two specialized health facilities in Kisangani (University Clinics of Kisangani and “Clinique des Anges Kisangani”). The population included 148 patients, 74 of whom were on clomiphene citrate + sildenafil citrate (CCSC) regimens and 74 of whom were on clomiphene citrate + estradiol valerate (CCEV) regimens for three months. The primary indicator was the conception rate, with secondary outcomes encompassing endometrial thickness, appearance and vascularity, the number of mature follicles and ovulation rate. The two groups were comparable in terms of sociodemographic and clinical characteristics. The mean duration of attempting to conceive was 4.39 years versus 4.36 years (P = 0.839), while the mean AFC was 11.51 versus 11.46 (P = 0.831), in the CCSC group versus CCEV group respectively. Secondary infertility was the most frequent diagnosis in each of the two groups. The biochemical pregnancy rate was comparable between the two groups (P = 0.385), while the clinical pregnancy rate was significantly higher in the CCSC group versus CCEV group (P = 0.04). Both perifollicular flow and the ovulation rate were significantly higher in the CCSC group versus the CCEV group (P = 0.006 and P = 0.002 respectively). However, endometrial vascularity/thickness, and the number of Graafian follicles were not significantly different between the two groups. As an adjuvant, sildenafil increases the rate of clinical pregnancy more than does estradiol in patients with unexplained infertility undergoing ovarian stimulation with clomiphene citrate. PACTR 202,310,849,449,401 (Pan African Clinical Trials Registry).